Spliceosomic profiling in pheochromocytomas and paragangliomas reveals alterations associated with clinico-molecular features and unveils RBM39 as a therapeutic target
This study reveals that splicing machinery is broadly dysregulated in pheochromocytomas and paragangliomas, identifying CELF4 as a biomarker for molecular stratification and RBM39 as a therapeutic target whose inhibition effectively suppresses tumor growth.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Inside the human body, a complex network of instructions tells cells how to build the proteins they need to function. These instructions are written in a molecule called RNA, which acts as a temporary copy of the genetic code stored in DNA. However, the initial copy is often too long and contains extra sections that must be removed before the cell can use the message. The cellular machinery that performs this editing process is called the spliceosome. It works like a pair of molecular scissors, cutting out the unnecessary parts and stitching the remaining pieces together to create a final, usable instruction. When this editing process goes wrong, the resulting proteins can be defective, leading to diseases including cancer. In recent years, scientists have discovered that many tumors hijack this editing system, using it to create abnormal proteins that help the cancer grow and spread.
Pheochromocytomas and paragangliomas are rare tumors that arise from nerve cells in the adrenal glands or along the spine. While they often grow slowly, they can become dangerous if they spread to other parts of the body, and current treatments for advanced cases are limited. For a long time, researchers have studied the genetic mutations that cause these tumors, but the role of the RNA editing machinery in these specific cancers remained a mystery. A team of scientists set out to fill this gap, asking whether the way these tumors edit their RNA instructions differs from healthy tissue and from each other, and whether fixing these errors could offer a new way to treat the disease.
The researchers began by examining the genetic data from hundreds of patients with these tumors, comparing them to healthy tissue. They found that the RNA editing machinery was indeed behaving differently in the tumors. The patterns of how these tumors cut and stitched their RNA were so distinct that the scientists could accurately tell the difference between tumors arising in the adrenal glands and those arising elsewhere in the body, simply by looking at how the editing was happening. This was a significant discovery because it revealed a hidden layer of difference between these two types of tumors that previous studies had missed. Furthermore, the team found that the specific way the editing machinery was altered could predict whether a tumor was likely to spread to other parts of the body, suggesting that these editing patterns could serve as a useful tool for doctors to assess the risk a patient faces.
Among the many components of the editing machinery the team studied, one protein stood out as a key marker for distinguishing between the different types of tumors and their molecular subgroups. This protein, known as CELF4, was consistently different in tumors compared to healthy tissue and varied reliably between the different categories of the disease. Its ability to separate these groups was so strong that it could serve as a precise tool for classifying patients, helping to identify which specific type of tumor they have and how aggressive it might be. This finding suggests that looking at how RNA is edited could improve the way doctors currently categorize and manage these rare cancers.
The investigation then turned to finding a specific target for treatment. The researchers analyzed the data to see if the levels of any editing proteins were linked to how long patients survived. They discovered that high levels of a protein called RBM39 were strongly associated with a poorer outcome for patients with both types of tumors. This protein appeared to be a critical vulnerability for the cancer cells. To test if targeting this protein could stop the tumor, the team used a drug called indisulam, which is known to break down RBM39. In laboratory experiments using human tumor cells, removing or degrading this protein caused the cells to stop growing and lose their ability to form new colonies. The drug also reduced the cells' ability to move, a key step in the spread of cancer.
To see if these results held true in a living system, the researchers tested the drug in mice that had been implanted with human tumor cells. The mice were treated with the drug for five consecutive days. The results showed that the treatment significantly slowed the growth of the tumors in the mice, without causing the animals to lose weight or show signs of sickness. This indicated that the drug could effectively attack the tumor while sparing the rest of the body. The study also revealed that the drug worked by disrupting the editing of specific genes involved in repairing DNA damage, essentially breaking the tumor's ability to fix its own genetic mistakes. While some tumor models showed a slightly weaker response than others, the overall effect was a clear reduction in tumor growth.
These findings suggest that the way these tumors edit their RNA instructions is not just a side effect of the disease, but a central feature that drives their behavior and offers a new path for treatment. The study identifies a specific protein, RBM39, as a promising target for therapy and demonstrates that drugs capable of degrading this protein can shrink tumors in preclinical models. While more research is needed to confirm these results in human patients, the work provides a strong reason to explore treatments that target the RNA editing machinery. It opens a door to a new strategy for fighting these rare and challenging tumors, moving beyond the current reliance on surgery and offering hope for patients with advanced disease.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.